AUG 11, 2015 09:09 PM PDT

Fast Tracking Promising Parkinson's Drug

A drug already been in use to treat liver disease may slow down the progression of Parkinson's disease, according to scientists from the University of Sheffield in the United Kingdom. Researchers from the Sheffield Institute of Translational Neuroscience (SITraN), in collaboration with scientists from the University of York, believe that their findings support the fast-tracking of the drug ursodeoxycholic acid (UDCA) for a clinical trial in Parkinson's patients, as published in the journal Neurology and reported in Drug Discovery & Development (http://www.dddmag.com/news/2015/08/promising-drug-parkinsons-disease-study-supports-fast-track-clinical-trials?et_cid=4731052&et_rid=45505806&type=cta).
UK researchers try to fast track drug currently used for liver disease and apply it to Parkinson's.
As the Mayo Clinic explains, Parkinson's disease is a progressive disorder of the nervous system that affects movement. It develops gradually, sometimes starting with a barely noticeable tremor in just one hand. While a tremor may be the most well-known sign of Parkinson's disease, the disorder also commonly causes stiffness or slowing of movement (http://www.mayoclinic.org/diseases-conditions/parkinsons-disease/basics/definition/con-20028488).

According to Dr Heather Mortiboys, Parkinson's UK Senior Research Fellow from the University of Sheffield, "We demonstrated the beneficial effects of UDCA in the tissue of LRRK2 carriers with Parkinson's disease as well as currently asymptomatic LRRK2 carriers. In both cases, UDCA improved mitochondrial function as demonstrated by the increase in oxygen consumption and cellular energy levels."

Oliver Bandmann, Professor of Movement Disorders Neurology at the University of Sheffield and Honorary Consultant Neurologist at Sheffield Teaching Hospitals NHS Foundation Trust, said that he hopes "the UDCA might be beneficial for other types of Parkinson's disease and might also show benefits in other neurodegenerative diseases." With good results from the in vitro drug screen, the researchers wanted to further investigate and confirm the potential of UDCA in vivo - in a living organism," he said.

According to the study, which was funded by Parkinson's UK, the Wellcome Trust and the Norwegian Parkinson Foundation, while a mutation in the LRRK2 gene is the single most common inherited cause of Parkinson's disease, the exact mechanism that leads to Parkinson's is not clear. Mitochondria defects play a role in many diseases that affect the nervous system, including Parkinson's and Motor Neuron Disease. Because nerve cells have high energy demands, defects in the cell's energy generators will affect their survival.

Collaborators Rebecca Furmston, White Rose PhD student, and Dr Chris Elliott, from the University of York's Department of Biology, showed the effects of UDCA in vivo on the fruit fly (Drosophila melanogaster). In fruit flies, the mitochondrial defects caused by the LRRK2 mutation to dopaminergic neurons can be monitored through the progressive loss of visual function. Flies carrying the mutation maintained their visual response when fed with UDCA, demonstrating the rescue of dopaminergic signaling. The researchers believe that testing the drug, which is already approved for other uses, could save considerable time and money while meeting the urgent needs of patients with Parkinson's disease.
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
SEP 24, 2018
Drug Discovery
SEP 24, 2018
Further Challenges in Alzheimer Drug Development
Scientists at Trinity College Dublin performed a large-scale international study involving the treatment of Alzheimer's disease, which was published in...
OCT 04, 2018
Cannabis Sciences
OCT 04, 2018
Why Does Marijuana Get You High?
With all this new research finally coming out about the effects of marijuana on various subjects (effects on mental health, prenatal exposure, adolescents,...
OCT 04, 2018
Neuroscience
OCT 04, 2018
Breast Milk is Brain Food for Preemies
A due date for a baby represents great hope to parents and families. Any due date is an educated guess, and some babies arrive a little early or a little l...
OCT 11, 2018
Neuroscience
OCT 11, 2018
Can Sleep Deprivation in Teens Increase Risk-Taking?
Getting enough sleep is a healthy habit for anyone, but in adolescents it's crucial. Brain development is happening at a rapid pace during the teen yea...
OCT 31, 2018
Health & Medicine
OCT 31, 2018
Small Animal Phobia and Virtual reality
Using digital technology for effective treatment of small animal phobia...
NOV 01, 2018
Cell & Molecular Biology
NOV 01, 2018
Researchers Link Parkinson's Disease and the Appendix
When a person's appendix is removed early in life, it reduces their chances of getting Parkinson's disease....
Loading Comments...